Selective RPE Laser Treatment (SRT) for Various Macular Diseases
Recruitment status was: Active, not recruiting
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens. The macular diseases to be treated are drusen maculopathy and geographic atrophy due to age-related macular degeneration as well as diabetic macular edema and central serous chorioretinopathy.
The beneficial effect in laser treatment is thought to be associated with the restoration of a new barrier of retinal pigment epithelium cells. If this theory is true, the destruction of the photoreceptors causing visual field defects would be only an unwanted and unnecessary side effect. Thus, SRT is able to avoid these unintentional side effects and to achieve the benefit by just treating the RPE.
In this study the clinical effect of SRT for these diseases is evaluated on a long-term basis.
|Age-Related Macular Degeneration Diabetic Maculopathy Central Serous Chorioretinopathy||Procedure: Selective RPE laser treatment|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
|Official Title:||Selective RPE Laser Treatment (SRT) for Various Macular Diseases|
- Visual acuity [ Time Frame: up to 2 years ]
- drusen reduction [ Time Frame: up to 2 years ]
- area of geographic atrophy [ Time Frame: up to 2 years ]
- reduction of retinal edema [ Time Frame: up to 2 years ]
|Study Start Date:||October 2004|
|Estimated Study Completion Date:||August 2010|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
Procedure: Selective RPE laser treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403884
|University Eye Hospital Regensburg|
|Regensburg, Germany, 93042|
|Principal Investigator:||Carsten Framme, MD||University Eye Hospital Regensburg|